The review presents recent developments in the identification of specialized proresolving mediators (SPMs) of inflammation following supplementation with n-3 fatty acids in humans.
INTRODUCTION
There is a large body of evidence from epidemiological and animal studies as well as clinical trials in humans providing support for a cardioprotective effect of the long-chain n-3 fatty acids, eicosapentaenoic acid (EPA, 20 : 5n-3), and docosahexaenoic acid (DHA, 22 : 6n-3) [1 & ]. Supplementation with n-3 fatty acids in humans has been shown to improve cardiovascular risk factors including lipid metabolism, blood pressure and vascular reactivity, and arterial compliance and cardiac function. In addition, n-3 fatty acids have antithrombotic, antioxidative, and anti-inflammatory actions [1 & ]. The ability of n-3 fatty acids to improve clinical outcomes in conditions associated with inflammation has been extensively reviewed [2 & ]. There is good evidence that n-3 fatty acids reduce joint inflammation associated with rheumatoid arthritis, and that patient assessment of joint pain, morning stiffness, and use of NSAIDs was reduced with n-3 fatty acids [2 & ]. The evidence for a beneficial effect of n-3 fatty acids in airway inflammation and intestinal inflammatory disease is strongest in animal models. Randomized controlled trials of n-3 fatty acids in humans with asthma or intestinal inflammatory disease provide only limited evidence of any clinical benefit [2 & ].
The mechanisms by which n-3 fatty acids exert their effects are still emerging but alterations in cell membrane composition, receptor signaling, and gene expression are all likely to be important. The anti-inflammatory protection attributed to n-3 fatty acids has focused on their effects on eicosanoid synthesis and leukocyte-derived cytokine formation [3] . For example, n-3 fatty acid-derived 3-series prostanoids and 5-series leukotrienes are substantially less potent than those formed from arachidonic acid.
Inflammation resolution is now recognized as an important mechanism that can be targeted to prevent chronic inflammation. Recent studies identifying specialized proresolving mediators (SPMs) of inflammation resolution that derive from EPA and DHA suggest that this may be a relevant mechanism that can be stimulated by n-3 fatty acid supplementation.
The current review will provide an overview of the biosynthesis of SPM and a summary of the effect of n-3 fatty acid supplementation studies on SPMs in humans. The identification and bioactivity of novel SPMs derived from n-3 fatty acids will be discussed.
Biosynthesis of specialized proresolving mediators derived from eicosapentaenoic acid and docosahexaenoic acid
SPMs are synthesized by transcellular processes and involve enzymes present in epithelial cells and leukocytes [4 && ]. EPA and DHA produce SPMs known as E-series and D-series resolvins, respectively. The action of acetylated cyclooxygenase-2 (COX-2) or cytochrome P450 monooxygenases on EPA results in formation of the unstable 18-hydroperoxyeicosapentaenoic acid (18-HpHEPE) and the intermediate 18-hydroxyeicosapentaenoic acid (18-HEPE) ( Fig. 1 ). 18-HEPE is converted by 5-lipoxygenase (5-LOX) to RvE1 or RvE2 [5] . In humans, RvE3 can be generated from EPA by the 15-lipoxygenase enzyme 1 (15-LOX) [6] (Fig. 1) . Collectively, EPAderived SPMs are known as the E-series resolvins (RvE1, RvE2, and RvE3). Their stereochemistry depends on whether initial synthesis involves acetylated COX-2 that predominantly produces 18R-HpHEPE rather than 18S-HpHEPE, leading to the 18R-E series resolvins that are also known as aspirin-triggered E-series resolvins.
DHA is a substrate for acetylated COX-2, cytochrome P450, and 15-LOX. D-Series resolvin synthesis occurs via formation of 17-hydroperoxydocosahexaenoic acid (17-HpDHA) and 17-hydroxydocosahexaenoic acid (17-HDHA) (Fig. 1 ). The action of 5-LOX KEY POINTS n-3 Fatty acid-derived SPMs play an important role in the resolution of inflammation and maintaining homeostasis.
Supplementation with n-3 fatty acids is a logical step in providing sufficient substrate for SPM biosynthesis.
Further studies are needed to determine SPM profiles in patients with different chronic conditions and to examine whether n-3 fatty acid supplementation affects SPM levels and how they associate with clinical outcomes. EPA 20:5n-3 on 17-HDHA leads to the D-series resolvins RvD1-RvD6 that can differ in their stereochemistry at the 17 carbon position [7] depending on the whether synthesis of 17-HpDHA involves acetylated COX-2 [8] . In the absence of 5-LOX, protectin D1 (PD1) and 10S,17S-DiHDHA are formed from 17-HpDHA. In humans, DHA can also be metabolized by macrophage 12-LOX [9 & ] to 14-hydroperoxydocosahexaenoic acid (14-HpDHA) that leads to formation of 14-hydroxydocosahexaenoic acid (14-HDHA) and the maresins, MaR-1 and MaR-2 [9 & ,10] ( Fig. 1 ).
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Actions of specialized proresolving mediators in in vitro and animal models of inflammation
The majority of studies examining effects of SPMs in the resolution of inflammation have utilized cell cultures or animal models of disease. The proresolving actions of SPMs at sites of inflammation include cessation of neutrophil infiltration and enhancement of macrophage phagocytosis of apoptotic neutrophils, both of which prevent neutrophilmediated tissue damage [11 & ]. SPMs have been shown to reduce the principal signs of inflammation including edema, leukotriene synthesis and COX-2 expression, inflammatory cytokines, platelet activating factor, and formation of reactive oxygen species [11 & ]. The receptors mediating the actions of SPMs are G-protein coupled receptors. RvE1 binds to the leukotriene B4 receptor BLT1 on neutrophils and ChemR23 on platelets with high affinity [12], whereas RvD1 binds GPR32 and the lipoxin A4 receptor FPR2 [13] . Recently, the receptor for RvD2 in humans and mice has been identified as GPR18 [14 & ]. The actions of SPMs in animal models of disease have been extensively reviewed [4 && ] and include controlling inflammatory pain (RvE1, RvD1, 17R-RvD1, RvD2, and Mar1), accelerating wound healing in diabetes (RvD1), inhibiting secondary thrombosis and necrosis in burn injury (RvD2), preventing colitis (RvE1, RvD1, and RvD2), protection against reperfusion injury in the heart (RvE1), and inhibiting kidney fibrosis (RvE1 and RvD1). Recent studies also indicate that RvE1 given orally to rabbits attenuated atherosclerosis induced by diet or periodontitis [15] , and RvD1 injected subcutaneously to mice improved ventricular function following myocardial infarction [16] . The precursors to the E and D-series resolvins, 18-HEPE and 17-HDHA, are also biologically active. 18-HEPE has been shown to reduce maladaptive cardiac remodeling in mice [17 & ]. 17-HDHA modulates macrophage function, alleviates experimental colitis [18] , and can mediate B-cell differentiation to antibody secreting cells [19] . 17-HDHA and 14-HDHA are found esterified in phospholipids of microparticles shed into exudates during inflammation, suggestive of a novel way that provides substrate for synthesis of D-series resolvins and maresins [20] .
Specialized proresolving mediators in humans and the effect of n-3 fatty acid supplementation
In humans, plasma is the most readily available blood component for examination of SPM levels. Plasma SPMs can be measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) targeted to specific SPM or a lipidomic approach. Our group has used targeted LC-MS/MS with authentic SPM standards and an appropriate internal standard to identify and quantitate SPMs in human plasma [21, 22, 23 & ,24 && ] and tissue [25 & ]. There are currently enzyme immunoassay kits available for a limited number of SPMs.
Mas et al. [21] first described an LC-MS/MS method for measuring a number of plasma SPMs including 18-HEPE, 17-HDHA, RvD1, 17R-RvD1 RvD2, 10S,17S-DiHDHA, and PD1 in humans. The study also examined the effect of different blood collection methods on levels of SPMs. The levels of 18-HEPE, 17-HDHA, RvD1, 17R-RvD1, and RvD2 were all measurable in plasma from healthy humans after 3 weeks of 2.4 g/day n-3 fatty acid supplements and ranged between 20 and 200 pg/ml [21] .
Subsequent studies have examined the effect of n-3 fatty acids supplementation in relation to plasma SPM formation in healthy volunteers [21,23 & ,26]; patients suffering from chronic headaches [22] ; mild hypertriglyceridemia [27] ; chronic renal disease [24 && ]; and peripheral artery disease [28] .
The effect of short-term n-3 fatty acid supplementation and the additional effects of aspirin were studied in 20 healthy volunteers [23 & ]. They were given n-3 fatty acid supplements (2.4 g/day as 1.4 g/ day EPA and 1 g/day of DHA) for 7 days with randomization to receive aspirin or placebo in addition to n-3 fatty acids during the last 2 days. Plasma SPMs were measured at baseline, after 5 days of n-3 fatty acids, and after 7 days (i.e., after 2 days of aspirin or placebo in addition to n-3 fatty acids). At baseline, there were detectable levels of 18-HEPE, RvE1, RvE2, RvE3, and 18R-RvE3 that derive from EPA, and 17-HDHA, RvD1, 17R-RvD1, RvD2, 14-HDHA, that are synthesized from DHA. Chiral chromatography was used to separate and quantify the concentration of different epimers of 18-HEPE and 17-HDHA before and after aspirin. The study showed that n-3 fatty acid supplementation for 5 days significantly increased plasma levels of 18-HEPE, 17-HDHA, 14-HDHA, and RvE1. Aspirin taken for 2 days in addition to n-3 fatty acids did not differentially affect any SPMs [23 & ]. However, the ratio of 17R-HDHA to 17S-HDHA was significantly reduced by aspirin.
In a recent study examining bioactive products formed after fish oil supplementation, 12 volunteers were given a high dose of fish oil (17.6 g/day n-3 fatty acids as 9.7 g/day EPA and 7.9 g/day DHA) for an average of 24 days in an open trial [26] . Plasma RvE1, RvD1, PD1, PDX, and maresin were determined using a lipidomic approach before and after fish oil. The authors reported plasma levels of 1.0-1.2 pg/ml PD1 before fish oil and 2.7-4.1 pg/ml after fish oil, but did not detect RvE1, RvD1, PDX, or maresin. In the same report, SPMs were measured before and after an intravenous bolus of endotoxin that was administered to six volunteers who had taken 5 g/day n-3 fatty acids for 8 weeks. The authors reported that PD1 and PDX were present in plasma in low picograms quantities, but were unaffected by fish oil or endotoxin [26] . The study failed to detect any SPMs in urine after high-dose fish oil supplementation [26] .
Animal studies have shown that SPMs derived from both EPA and DHA have antinociceptive properties [29] . Ramsden et al. [22] examined plasma levels of 18-HEPE and 17-HDHA in a randomized, single-blind, parallel 12-week study of 67 patients that assessed the effect of targeted alteration in dietary n-3 and n-6 fatty acids on chronic headaches. The primary outcome was the Headache Impact Test-6 score, that is a commonly used measure of headache-related disability based on self-reported pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress. The study showed that a high n-3/low n-6 fatty acid intervention produced significantly greater improvement in the Headache Impact Test-6 score, number of headache days/month, and the duration of the headache, compared with the low n-6 fatty acid intervention. The precursors to the antinociceptive resolvins 18-HEPE and 17-HDHA were significantly elevated compared with the low n-6 fatty acid intervention. Further studies are required to assess whether specific resolvins involved in nociception are altered after n-3 fatty acid supplementation.
Hypertriglyceridemia is a risk factor for cardiovascular disease (CVD) and associated with lowgrade inflammation. n-3 fatty acid supplementation has been shown to be effective in reducing plasma triglycerides in patients with hypertriglyceridemia. In a controlled trial of 10 weeks, 53 patients with mild hypertriglyceridemia were randomized to one of three groups that were given a fruit yoghurt enriched with either n-3 fatty acids (0.8 g/day or 3 g/day) or placebo. The primary outcomes of the study were blood lipids (total cholesterol, triglycerides, and HDL and LDL-cholesterol) [27] . Plasma 18-HEPE was measured at baseline and after 10 weeks using a lipidomic approach in the 16 patients who received 3 g/day n-3 fatty acids. The authors reported a nonsignificant increase in 18-HEPE from baseline.
The high incidence of CVD in chronic kidney disease is related partially to chronic inflammation [30] . Mas et al. [24 && ] measured plasma SPMs in 74 patients with chronic renal disease randomized to n-3 fatty acids (1.84 g/day EPA and 1.52 g/day DHA) or coenzyme Q10 for 8 weeks. n-3 fatty acids significantly increased plasma levels of 18-HEPE, 17-HDHA, and RvD1 (Fig. 2) . Coenzyme Q10 had no effect on any plasma SPMs. In regression analysis, the increase in 18-HEPE and 17-HDHA following n-3 fatty acids was predicted by the change in platelet EPA and DHA, respectively.
The effect of n-3 fatty acid supplements on SPMs and other lipid mediators was studied in 80 patients with peripheral artery disease [28] . The study was a randomized double blind trial that gave patients either 4.4 g/day n-3 fatty acids or placebo for 1 month with endothelial function as the primary outcome [28] . Assessment of a number of SPMs in plasma using a lipidomic approach showed plasma 18-HEPE was significantly increased after n-3 fatty acids compared with the placebo group. Other SPMs including RvE1, 17-HDHA, 10,17-diHDHA, RvD1, RvD2, 7S,14S-diHDHA, and MaR1 were either not detected or not significantly altered.
Although most studies of n-3 fatty acid supplementation have measured SPMs in plasma, Keelan et al. [25 & ] measured SPMs in placental tissue of pregnant atopic women who were enrolled in a randomized, placebo controlled trial of n-3 fatty acid supplementation (3.7 g/day) from 20 weeks gestation until delivery. This study showed that 18-HEPE and 17-HDHA were two to three-fold higher in placenta of women supplemented with n-3 fatty acids. RvD1, 17R-RvD1, RvD2, and PD1 were detectable in all placentas, but concentrations were not significantly increased by n-3 fatty acids.
There are a number of factors that could explain the differences in levels of SPMs reported in human plasma after n-3 fatty acid supplementation. Studies vary with respect to the study design, dose, and duration of n-3 fatty acid supplementation, differences in patient characteristics, and the use of medications, all of which could affect SPM levels. The methodology used to measure SPMs is critical for their detection in human plasma. LC-MS/MS targeted to specific SPM as opposed to a lipidomic approach provides a more reliable means of measuring SPMs. Most of the studies to date have been opportunistic measuring plasma SPMs retrospectively. In some instances, SPMs were measured in a subset of patients from a clinical trial, and the studies may not have been adequately powered to detect differences in SPMs after n-3 fatty acids. Differences in collection and storage of plasma samples may have contributed to the wide variation in plasma SPMs. Future studies will benefit from the current literature of the variability of specific SPMs in plasma. This information can be utilized to design appropriately controlled studies to assess the role of plasma SPMs in relation to clinical outcomes after n-3 fatty acid supplementation.
Recently identified novel specialized proresolving mediators from n-3 fatty acids
In addition to the array of reported SPMs, novel metabolites derived from DHA and docosapentaenoic acid (DPA, 22 : 5n-3) have been recently described. Deng et al. [9 & ], showed that human macrophages produce 13R,14S-dihydroxy-docosahexaenoic acid (13R,14S-diDHA) from DHA. Biosynthesis of 13R,14S-diDHA involves 12-LOX with initial oxygenation of DHA, subsequent epoxidation of the 14-hydroperoxy-intermediate (14S-HpDHA) to 13S,14S-epoxy-maresin, followed by hydrolysis via soluble epoxide hydrolase. Given 13R,14S-diHDHA is formed from the same 13S,14S-epoxy-maresin as MaR1, the new SPM was termed maresin-2 (MaR2). MaR2 reduced neutrophil infiltration in mouse peritonitis and enhanced human macrophage phagocytosis of zymosan in a similar manner to MaR1, but was significantly less active in enhancing efferocytosis with human macrophages.
Using targeted lipidomics, Yokokura et al. [31] identified 14S,20R-diHDHA as a novel DHA-derived SPM in mouse inflammatory exudates. 14S,20R-diHDHA is produced by eosinophils through the 12/15-LOX pathway and limits neutrophil infiltration in zymosan-induced peritonitis [31] .
A new class of bioactive SPMs derived from DPA was reported by Dalli et al. [32] . SPMs identified in plasma from mice subjected to ischemia-reperfusion injury included RvD1 n-3 DPA , RvD2 n-3 DPA , RvD5 n-3 DPA , PD1 n-3 DPA , and PD2 n-3 DPA . Peritoneal exudates from zymosan-treated mice produced MaR1 n-3 DPA , MaR2 n-3 DPA , and MaR3 n-3 DPA in addition to those identified in plasma. When human neutrophils were incubated with zymosan and 1 mmol/l DPA, the products identified included RvD1 n-3 DPA , RvD2 n-3 DPA , RvD5 n-3 DPA , PD1 n-3 DPA , and MaR3 n-3 DPA . When administered in vivo, RvD1 n-3 DPA , RvD2 n-3 DPA , RvD5 n-3 DPA , PD1 n-3 DPA , MaR1 n-3 DPA , and MaR2 n-3 DPA each reduced neutrophil infiltration in murine peritonitis and showed cytokine counter-regulatory actions comparable to RvD2. The same SPMs reduced human neutrophil chemotaxis and adhesion to endothelial cells [32] . In another report, Dalli et al. [33 & ] showed that neutrophilendothelial cell coincubation in the presence of DPA and various stimuli generated four novel DPAderived SPMs termed 13-series resolvins (RvTs). These resolvins were identified as 7,13,20-trihydroxy-docosapentaenoic acid (RvT1), 7,8,13-trihydroxy-docosapentaenoic acid (RvT2), 7,12,13trihydroxy-docosapentaenoic acid (RvT3), and 7,13-dihydroxy-docosapentaenoic acid (RvT4) [33 & ]. The RvTs were elevated in blood of mice challenged with E. Coli, sepsis patients, and healthy volunteers after exercise. RvTs exhibited proresolving actions regulating host responses during E. Coli infection in mice and phagocytosis by isolated human cells. RvT biosynthesis via COX-2 was increased by statins and reduced by COX-2 inhibitors.
Further studies will be required to determine whether levels of any of the newly reported DHA or DPA-derived SPMs are increased following n-3 fatty acid supplementation. Most of the studies to date have entailed detection of these novel SPMs following in-vitro biosynthesis or after an acute inflammatory insult in small animal models. The one exception is the detection of RvTs in human plasma where basal levels were 1-2 pg/ml and increased to 3-5 pg/ml following exercise [33 & ]. Concentrations of RvTs in sepsis patients were 15-20 pg/ml [33 & ]. In contrast, basal plasma concentrations of E-series (25-70 pg/ml) and D-series (40-90 pg/ml) resolvins, as well as the precursors 18-HEPE (70-100 pg/ml), 17-HDHA (80-90 pg/ml), and 14-HDHA (220-380 pg/ml) in human plasma are substantially greater than RvTs [23 & ]. The significantly lower levels of RvTs may be because of the lower basal plasma concentrations of DPA (24 mmol/l) compared with EPA and DHA (40 and 89 mmol/l respectively) [34] . Furthermore, n-3 fatty acid intervention studies have consistently shown that EPA and DHA levels are increased to a much greater extent than DPA following supplementation. The finding that RvTs are present in human plasma do not preclude the fact that these SPMs may play a greater role in tissues where DPA levels are higher, such as in heart and skeletal muscles and kidneys.
CONCLUSION
The number of new SPMs that will be identified and characterized is likely to expand as a result of improvements in isolation techniques and instrumentation detection. It is also likely that a number of these SPMs will have varying degrees of proresolving bioactivity. However, it will be important to establish which SPMs are present in humans and whether their concentrations are sufficiently high to be relevant. It is also likely that SPM biosynthesis in humans will differ depending on the underlying pathophysiology, and research is required to establish SPM profiles in patients with different chronic conditions. With these criteria satisfied, supplementation with n-3 fatty acids remains a logical step in providing sufficient substrate for n-3 fatty acid-derived SPM biosynthesis. To date, supplementation studies in humans have consistently shown that n-3 fatty acids can increase plasma levels of a number of the E and D-series resolvins and their precursors 18-HEPE and 17-HDHA, respectively, as well as 14-HDHA, the upstream metabolite of the maresin family. Moreover, many of the plasma SPMs after n-3 fatty acids are present at concentrations that have been shown to have biological activity. Given that SPMs are regarded as autocoids released at the sites of inflammation, one might anticipate their concentration at the inflammatory site would be even higher than that in blood. Enhanced concentrations of SPMs after n-3 fatty acids adds substantial support to the overall concept of their capacity to suppress inflammation and provide benefit against CVD.
